Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28126126 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL6638235 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL4372827 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL30134233 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL6638354 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL27508297 | 0.83 | CYP1A2 (0.50) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL27467264 | 0.82 | CYP1A2 (0.48) | CYP1A2CYP2A6PDPK1NPC1GRM4 | |
| SCHEMBL24312379 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL12045702 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2A6PDPK1NPC1RAB9A | |
| SCHEMBL12938122 | 0.79 | GRM4 (0.38) | GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3334464-B1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | MASSACHUSETTS GEN HOSPITAL (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130627-A2 | METHODS FOR TREATING HEPATITIS C | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | CYP1A2 4855/4885CYP2A6 4848/4885PDPK1 1983/4885 |
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | CYP1A2 4109/4885CYP2A6 3667/4885PDPK1 330/4885 |
| US-20230373974-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP1A2 4609/4885CYP2A6 4006/4885PDPK1 1661/4885 |
| US-11858880-B2 | Anti-fungals compounds targeting the synthesis of fungal sphingolipids | ERG28, UGCG, DPM1 | CYP1A2 3604/4885CYP2A6 3878/4885PDPK1 406/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | CYP1A2 4591/4885CYP2A6 3981/4885PDPK1 149/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | CYP1A2 3859/4885CYP2A6 4314/4885PDPK1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.